Wikipedia

Fazio–Londe disease

(Redirected from Fazio-Londe syndrome)

Fazio–Londe disease (FLD), also called progressive bulbar palsy of childhood,[1][2] is a very rare inherited motor neuron disease of children and young adults and is characterized by progressive paralysis of muscles innervated by cranial nerves. FLD, along with Brown–Vialetto–Van Laere syndrome (BVVL), are the two forms of infantile progressive bulbar palsy,[3] a type of progressive bulbar palsy in children.

Fazio–Londe disease
Other namesProgressive bulbar palsy of childhood
This condition has an autosomal recessive mode of inheritance
SpecialtyNeurology Edit this on Wikidata

Signs and symptoms

edit

FLD produces rapidly progressive weakness of tongue, face and pharyngeal muscles in a clinical pattern similar to myasthenia. Neuromuscular transmission may be abnormal in these muscles because of rapid denervation and immature reinnervation. Paralysis occurs secondary to degeneration of the motor neurons of the brain stem. It causes progressive bulbar paralysis due to involvement of motor neurons of the cranial nerve nuclei. The most frequent symptoms at onset of progressive bulbar paralysis of childhood has been a unilateral facial paralysis. It is followed in frequency by dysarthria due to facial weakness or by dysphagia. Palatal weakness and palpebral ptosis also have been reported in few patients. Both sexes can be affected.[4][5][additional citation(s) needed]

Genetics

edit

Fazio–Londe disease is linked to a genetic mutation in the SLC52A3 gene on chromosome 20 (locus: 20p13).[1] It is allelic and phenotypically similar to Brown–Vialetto–Van Laere syndrome.[1][6] The condition is inherited in an autosomal recessive manner.[1] The gene encodes the intestinal riboflavin transporter (hRFT2).[7]

Diagnosis

edit

Symptoms of Fazio–Londe include bulbar palsy, hearing loss, facial weakness, and difficulty breathing. The disease is caused by mutations in the SLC52A2 gene and the SLC52A1 (GPR172B) genes which code for hRFT3 and hRFT1, human riboflavin transporters. Only muscle biopsy and examination of the transporter genes is considered to provide a definitive diagnosis. However, because the disease is so often fatal without treatment, and because the treatment is so inexpensive and with little risk, it is recommended that if the disease is suspected that riboflavin therapy be started immediately while testing is in progress.[8]

Treatment

edit

The condition is treatable.[9] High doses of oral riboflavin 5 phosphate may work,[8] and sublingual flavin adenine dinucleotide may work.[10]

Prognosis

edit

Onset of first symptom has been reported between 1–12 years, with a mean age of onset at 8 years. Clinical course can be divided into early (< 6 yrs age, predominance of respiratory symptoms) and late course (6–20 years of age, predominance of motor symptoms on superior limbs). Progression to involve other cranial nerve muscles occurs over a period of months or years. In the Gomez review, the facial nerve was affected in all cases while the hypoglossal nerve was involved in all cases except one. Other cranial nerves involved were vagus, trigeminal, spinal accessory nerve, abducens, oculomotor, and glossopharyngeal in this order. Corticospinal tract signs were found in 2 of the 14 patients.[citation needed]

The disease may progress to patient's death in a period as short as 9 months or may have a slow evolution or may show plateaus. Postmortem examination of cases have found depletion of nerve cells in the nuclei of cranial nerves. The histologic alterations found in patient with Fazio–Londe disease were identical to those seen in infantile-onset spinal muscular atrophy.[citation needed]

Strength may improve with administration of cholinesterase inhibitors.[citation needed]

History

edit

Berger, in 1876, first reported a case of 12-year-old boy with progressive bulbar paralysis. His medical history revealed a neurological illness with difficulty in swallowing liquids and solids, nasal regurgitation to liquids, nasal twang 2 years ago. He was treated for post-diptheritic bulbar palsy and had a residual bulbar weakness. Other details were not available. The child was ambulant and apparently normal until 3 months back when he developed respiratory distress and was treated at a local hospital prior to referral. He had a past history of dog bite 3 months ago for which he received five doses of anti-rabies vaccine. He was born out of a non-consanguineous marriage. The antenatal, natal, postnatal histories were insignificant. His elder sibling was healthy. This child was immunised appropriate for age. There was no family history of any neurological illness or sibling death.[11]

Eponym

edit

It is named for the Italian pathologist Eugenio Fazio (1849–1902) and the French physician Paul Frederic Louis Londe (1864–1944).[12][13]

References

edit
  1. ^ a b c d Online Mendelian Inheritance in Man (OMIM): 211500
  2. ^ McShane, MA; Boyd, S; Harding, B; Brett, EM; Wilson, J (December 1992). "Progressive bulbar paralysis of childhood. A reappraisal of Fazio-Londe disease". Brain: A Journal of Neurology. 115 (Pt 6): 1889–900. doi:10.1093/brain/115.6.1889. PMID 1486466.
  3. ^ Piña-Garza, J. Eric (2013). Fenichel's Clinical Pediatric Neurology E-Book: A Signs and Symptoms Approach. Elsevier Health Sciences. p. 328. ISBN 978-1455748129. Retrieved 5 December 2017.
  4. ^ "OMIM Entry - # 211500 - FAZIO-LONDE DISEASE". www.omim.org. Retrieved 18 July 2021.
  5. ^ "Fazio-Londe Disease - Tests - GTR - NCBI". www.ncbi.nlm.nih.gov. Retrieved 18 July 2021.
  6. ^ Dipti S, Childs AM, Livingston JH, et al. (September 2005). "Brown–Vialetto–Van Laere syndrome; variability in age at onset and disease progression highlighting the phenotypic overlap with Fazio–Londe disease". Brain Dev. 27 (6): 443–446. doi:10.1016/j.braindev.2004.10.003. PMID 16122634. S2CID 32223440.
  7. ^ "SLC52A3 solute carrier family 52 member 3 [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2024-09-12.
  8. ^ a b Bosch, Annet M; Stroek, Kevin; Abeling, Nico G; Waterham, Hans R; IJIst, Loedijk; Wanders, Ronald JA (2012). "The Brown-Vialetto-Van Laere and Fazio Londe syndrome revisited: natural history, genetics, treatment and future perspectives". Orphanet Journal of Rare Diseases. 7. BMC: 83. doi:10.1186/1750-1172-7-83. PMC 3517535. PMID 23107375.
  9. ^ Varadarajan, Poovazhagi; Thayanathi, Vimal; Pauline, LeemaC (2014). "Fazio Londe syndrome: A treatable disorder". Annals of Indian Academy of Neurology. 18 (1): 87–9. doi:10.4103/0972-2327.144283. PMC 4350224. PMID 25745320.
  10. ^ Abdi, Mohammad; Jolfaei, Maryam; Ghasemi, Maryam; Dinmohammadi, Mohammad; Hojjat, Torkmandi; Khademi, Elmira (2020). "Fazio-Londe Syndrome and Patient-centered Nursing Care: A Case Report" (PDF). Client-Centered Nursing Care. 6 (2): 139 – via Semantic Scholar.
  11. ^ Poovazhagi Varadarajan, Vimal Thayanathi, and Leema C. Pauline. (2015). Fazio Londe syndrome: A treatable disorder. Ann Indian Acad Neurol, 18(1), 87-89
  12. ^ synd/1909 at Who Named It?
  13. ^ Londe, P. Paralysie bulbaire progressive, infantile et familiale. Rev. Med. 14: 212–254, 1894.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Fazio–Londe_disease&oldid=1247091827"
  NODES
admin 1
Note 1